Oak Ridge Investments LLC Purchases 6,412 Shares of Celgene Corporation (CELG)
Oak Ridge Investments LLC raised its position in Celgene Corporation (NASDAQ:CELG) by 4.2% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 157,997 shares of the biopharmaceutical company’s stock after acquiring an additional 6,412 shares during the quarter. Oak Ridge Investments LLC’s holdings in Celgene Corporation were worth $20,519,000 as of its most recent SEC filing.
Other institutional investors have also recently modified their holdings of the company. Neuberger Berman Group LLC lifted its stake in Celgene Corporation by 4.0% in the first quarter. Neuberger Berman Group LLC now owns 1,844,837 shares of the biopharmaceutical company’s stock worth $229,553,000 after acquiring an additional 71,729 shares during the last quarter. Grisanti Capital Management LLC purchased a new position in Celgene Corporation in the second quarter worth approximately $3,616,000. Lincoln Capital Corp lifted its stake in Celgene Corporation by 0.6% in the second quarter. Lincoln Capital Corp now owns 30,580 shares of the biopharmaceutical company’s stock worth $3,971,000 after acquiring an additional 185 shares during the last quarter. RiverPoint Capital Management LLC lifted its stake in Celgene Corporation by 3.1% in the second quarter. RiverPoint Capital Management LLC now owns 121,654 shares of the biopharmaceutical company’s stock worth $15,799,000 after acquiring an additional 3,680 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its stake in Celgene Corporation by 9.2% in the second quarter. Russell Investments Group Ltd. now owns 641,697 shares of the biopharmaceutical company’s stock worth $83,344,000 after acquiring an additional 54,210 shares during the last quarter. Institutional investors own 79.16% of the company’s stock.
Celgene Corporation (NASDAQ:CELG) opened at $100.34 on Thursday. Celgene Corporation has a 1-year low of $94.55 and a 1-year high of $147.17. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52. The company has a market cap of $77,834.16, a price-to-earnings ratio of 15.45, a PEG ratio of 0.76 and a beta of 1.79.
Celgene Corporation (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating analysts’ consensus estimates of $1.87 by $0.04. Celgene Corporation had a net margin of 27.36% and a return on equity of 63.80%. The firm had revenue of $3.29 billion for the quarter, compared to analyst estimates of $3.42 billion. During the same period last year, the firm posted $1.58 EPS. Celgene Corporation’s quarterly revenue was up 10.2% on a year-over-year basis. analysts predict that Celgene Corporation will post 6.67 earnings per share for the current fiscal year.
CELG has been the subject of a number of recent research reports. Jefferies Group LLC reiterated a “buy” rating and issued a $160.00 price target on shares of Celgene Corporation in a research note on Monday, July 31st. Cantor Fitzgerald set a $160.00 price objective on shares of Celgene Corporation and gave the stock a “buy” rating in a report on Thursday, July 27th. Mizuho set a $134.00 price objective on shares of Celgene Corporation and gave the stock a “buy” rating in a report on Wednesday, July 26th. Canaccord Genuity set a $156.00 price objective on shares of Celgene Corporation and gave the stock a “buy” rating in a report on Thursday, July 27th. Finally, Stifel Nicolaus assumed coverage on shares of Celgene Corporation in a report on Friday, July 28th. They set a “buy” rating and a $155.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating, nineteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $139.64.
In related news, insider Terrie Curran sold 1,727 shares of Celgene Corporation stock in a transaction on Monday, September 25th. The shares were sold at an average price of $143.89, for a total value of $248,498.03. Following the transaction, the insider now directly owns 3,925 shares in the company, valued at approximately $564,768.25. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Gilla Kaplan sold 9,250 shares of Celgene Corporation stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total transaction of $1,309,430.00. Following the completion of the transaction, the director now owns 85,551 shares in the company, valued at $12,110,599.56. The disclosure for this sale can be found here. Over the last quarter, insiders sold 20,227 shares of company stock worth $2,843,956. 0.95% of the stock is currently owned by insiders.
About Celgene Corporation
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.